Finnish company claims its test is the first to

Investment will fund VNA-318, Vandria’s lead t

Company taps into Pfizer’s Boulder team as it

New data-powered digital health platform Thrive

New research reveals that certain antidiabetic d

Precision-fermented version of lactoferrin is li

Amid increasing concern over the validity of lon

MIT spinout leverages single strand DNA to ‘br

New clinical trial suggests donor stem cell trea

Company targets US metabolic health crisis, rais

Stanford Medicine study reveals we experience tw

Treating Alzheimer’s patients with combination

When you use links on our website, we may earn a f

The 11th ARDD conference will feature a star-stu

Topical treatment is designed to reactivate dorm

José Cordeiro and Felix Werth explore how the d

Genetic testing firm closes drug discovery divis

Researchers develop new method to create complex

Partnership aims to bring C2N’s portfolio of A

Preclinical study investigates neuron-targeted p

Unified company aims to ‘industrialize drug di

Bioniq founder on why taking a personalized appr

Companies seek to leverage disease risk detectio

Longevity world mourns a pioneer of aging resear

Company targets Phase 2 trial of oral Alzheimer’s drug that inhibits the activity of microglia to combat neuroinflammation. US biotech NeuroTherapia has secured $12.3 million in the first close of a Series B financing round to progress its mission to tackle central nervous system diseases, with an initial focus on Alzheimer’s. While many companies are targeting the removal of toxic proteins like beta amyloid, tau and alpha synuclein, the Cleveland Clinic spinout is addressing neuroinflammation, a factor increasingly recognized as crucial in the progression of CNS diseases. NeuroTherapia’s focus is on developing orally available small-molecule drugs that inhibit the activity of microglia, immune cells in the CNS that contribute to neuroinflammation. By modulating these cells, the company aims to reduce inflammation without disrupting the clearance of toxic proteins, thereby improving neuronal function and survival. Microglia, the central immune cells in the brain, can exist in two states: the neuroprotective M2 phenotype, which helps clear amyloid β, and the neurotoxic M1 phenotype, which contributes to inflammation and synaptic damage. In Alzheimer’s disease and other neurodegenerative conditions, there is an increased prevalence of the M1 state, exacerbating the disease. NeuroTherapia’s lead candidate, NTRX-07, is designed to activate the cannabinoid type 2 (CB2)…

New study shows that raising levels of fatty aci

On a mission to promote healthier eating habits,

Transferring regeneration-associated genes from

Company announces PIPE financing of up to $122 m

Part of $27 million fund to foster collaboration

New Alzheimer’s drug data highlights increased

Study identifies the nuclear protein Pin1 as piv

Seed round led by SV Health and Two Bear Capital

Study shows Shingrix vaccine may delay dementia

Cognition Therapeutics reports once-daily drug’s potential to slow Alzheimer’s progression, showing promise with favorable safety profile. Cognition Therapeutics, Inc. recently disclosed findings from their Phase 2 SHINE trial, investigating the efficacy of CT1812, an experimental oral treatment for Alzheimer’s disease. The study, which involved 153 adults with mild-to-moderate Alzheimer’s, assessed the cognitive and functional impacts of daily CT1812 doses over six months, and has reported approximately 40% less cognitive decline in patients administered CT1812 compared with those on a placebo. The SHINE trial, a double-blind, placebo-controlled study, explored two dosages of CT1812 (100mg and 300mg), with the primary objective being the safety and tolerability of the treatment. The drug showed a consistent trend towards cognitive improvement across multiple measures, including an Alzheimer’s Disease Assessment Scale that involved 11 different tasks (ADAS-Cog 11) and a Mini-Mental State Examination based on 11 questions (MMSE). Specifically, by Day 182, participants on placebo experienced a 2.70-point decline on the ADAS-Cog 11 scale, while those on CT1812 showed a lesser decline of 1.66 points – indicating a 39% reduction in cognitive decline in favor of the treatment. Dr Anthony Caggiano, Chief Medical Officer of Cognition Therapeutics, remarked: “A key objective of this trial was to provide…

Recent study indicates that hyperbaric oxygen th

New research highlights inconsistency in lifespa

Crossbench peer urges UK Parliament to consider

Season finale to The Kardashians sees the family

Citing rise in GLP-1 popularity, longevity biote

ChromaDex partners with 1health to launch test k

BioXtek CEO Dr Bruce Werber on a new healing par

Company aims to offer at-home clinical trial ser

Pilot study explores low-dose rapamycin’s pote

Company identifies calcium signaling in the brai

Naturally occurring peptide, PEPITEM, shows prom

Shanghai-based company has multiple programs tar

Inhibiting inflammatory protein interleukin-11 l

Longevity clinic at Bumrungrad Hospital adopts p

Longeveron CEO: Lomecel-B simultaneously targets